Pharma Firms Keep A Close Eye On NICE's New HTA Approach In UK
Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.
You may also be interested in...
ABPI calls on UK to address lower investments in new medicines compared with comparable markets.
NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.
The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines access from 2024 onwards.